Equinor ASA (OSE: EQNR, NYSE: EQNR) announced on 29 October 2025 a cash dividend per share of USD 0.37 for third quarter 2025. The NOK cash dividend per share is based on average USDNOK fixing rate from Norges Bank in the period plus/minus three business days from record date 17 February 2026, in total seven business days. Average Norges Bank fixing rate for this period was 9.5267. Total cash dividend for third quarter 2025 is consequently NOK 3.5249 per share. On 27 February 2026, the cash dividend will be paid to relevant shareholders on Oslo Børs (Oslo Stock Exchange) and to holders of American Depositary Receipts (“ADRs”) on New York Stock Exchange. This information is published in accordance with the requirements of the Continuing Obligations and is subject to the disclosure requirements pursuant to section 5-12 of the...

The intensive exploration campaign aims to extend known mineralisation, drill recently defined targets and identify new prospects as part of the strategy to drive value through resource growth Chibougamau Copper-Gold Project, Canada HIGHLIGHTS:Cygnus sets up value drivers for 2026 with exploration and resource growth a high priority At Cedar Bay, Downhole Electromagnetics (‘DHEM’) is in progress to identify follow-up targets from recent intersections1 such as:28.9m at 2.5g/t AuEq (1.0g/t Au, 1.0% Cu & 12.0g/t Ag) (CDR-25-16) 10.6m at 4.1g/t AuEq (3.6g/t Au, 0.3% Cu & 2.8g/t Ag) (CDR-25-11W1)This is the first time DHEM is being used at Cedar Bay in over 20 years Drilling has started at Golden Eye to test extensions below the current resource, which stands at 0.5Mt at 5.6g/t AuEq for 91koz AuEq (Indicated) and 1.2Mt at...

– Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD – – Oral presentation on Phase 3 trial design for z-basivarsen in DM1 – – Five total presentations across three neuromuscular diseases demonstrate strength of Dyne’s pipeline based on clinically-validated FORCE™ platform – WALTHAM, Mass., Feb. 22, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that five presentations, including three oral presentations, highlighting the company’s Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and Pompe disease programs will be presented at the...

CALGARY, Alberta, Feb. 22, 2026 (GLOBE NEWSWIRE) — (“Canacol” or the “Company”) announces a leadership change and the appointment of an independent director to the board of directors (the “Board”). The Board believes that these changes will position the Company for success in the next phase of its restructuring by adding substantial restructuring experience to the Board. Mr. Jason Bednar, Canacol’s Chief Financial Officer, and Mr. Ravi Sharma, Canacol’s Chief Operating Officer, will assume roles as Interim Co-Chief Executive Officers of the Company effective immediately. Mr. Bednar will continue in his role as Chief Financial Officer and Mr. Sharma will continue in his role as Chief Operating Officer while also assuming the responsibilities as Interim Co-Chief Executive Officers. In this role, they will jointly oversee the Company’s...

LONDON, Feb. 22, 2026 (GLOBE NEWSWIRE) — nVent Electric plc (NYSE: NVT) (“nVent”), a global leader in electrical connection and protection solutions, today announced that it is postponing its Investor Day, originally scheduled for February 24, 2026, due to a state of emergency declared for the New York metropolitan area ahead of a major winter storm, expected to bring blizzard conditions. nVent is currently evaluating scheduling options. A formal invitation will be issued once the new date and location are finalized. This postponement is strictly due to weather-related logistics and is not related to any change in the company’s operations, financial performance or outlook. About nVentnVent is a leading global provider of electrical connection and protection solutions. We believe our inventive electrical solutions enable safer systems...

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12 Consistently, other clinical and imaging scores also showed improvements of 80+% by week 12 for patients treated with SLK, including ASDAS-CRP and SPARCC MRI axSpA is a disease driven by inflammation leading to irreversible ossification (via osteoblast activity) and ultimately to irreversible restriction of mobility – objective PET/MRI imaging data further showed a significant reduction in inflammation and osteoblast activity deep in affected joints, already by week 12, suggesting potential for disease modification in axSpA for SLK As a biomarker-controlled trial, S-OLARIS data showed SLK reduced the levels of key inflammatory mediators in axSpA, in peripheral...

Press ReleaseVELIZY-VILLACOUBLAY, France — February 21, 2026 Dassault Systèmes’ CEO Pascal Daloz becomes also Chairman of the Board of Directors of Dassault SystèmesBernard Charlès announces stepping down from his Executive Chairman and Member of the Board positions, for personal reasons Bernard Charlès intends to put his 43 years of industry experience, and his vision to transform, with AI, industrial creation and production processes, at the service of the Generative Economy Pascal Daloz is appointed Chairman and Chief Executive Officer by Dassault Systèmes’ Board, pursuing the 3D UNIV+RSES ambition to position Dassault Systèmes as leader in Industrial AIDassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) announces that Bernard Charlès has informed the Board of Directors, today and with immediate effect, that he is stepping...

VANCOUVER, British Columbia, Feb. 21, 2026 (GLOBE NEWSWIRE) — ANORTECH INC. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTCQB “ANORF”) has granted incentive stock options under the Company’s stock option plan to directors, employees and consultants to purchase a total of 5,150,000 shares at a price of $0.10 per share. The options vest over 18 months and have a term of five years, subject to the policies of the TSX Venture Exchange. ON BEHALF OF THE BOARD OF DIRECTORS “Jim Cambon” President and Director For further information:Ph: 778-373-2164www.anortechinc.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 202622 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials demonstrates a favorable safety profile with rates of serious treatment emergent adverse events and study discontinuation similar to placebo Symptomatic response of obefazimod was observed as early as week...

Proposed $1.0 Million Convertible Debenture and Warrant Financing and Concurrent Common Share Private Placement Up to $1.0 Million Intended to Support Near-Term Operations VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that its previously announced financing has been upsized up to approximately $2 million. On January 27th, the Company announced that it has reached an agreement in principle with an existing investor to invest an additional $1.0 million in the Company by way of a non-brokered private placement (the “Debenture Private Placement”) of an unsecured convertible debenture and two million common share purchase...